These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: [Mavacamten: a promising new target drug for the treatment of hypertrophic cardiomyopathy].
    Author: Zhang YP, He B.
    Journal: Zhonghua Xin Xue Guan Bing Za Zhi; 2021 Apr 24; 49(4):310-313. PubMed ID: 33874678.
    Abstract:
    马瓦卡坦(mavacamten)是选择性心肌β肌球蛋白三磷酸腺苷酶变构抑制剂。临床前研究发现其能够降低肌节过度收缩和维持肌球蛋白过放松状态,小鼠实验发现其能逆转心室壁肥厚和纤维化进程,临床Ⅱ、Ⅲ期试验表明其能缓解肥厚型心肌病患者的临床症状,减轻左心室流出道梗阻,改善心功能、提高运动耐量。该文对mavacamten现有的3项临床研究进行了分析,以期增进心血管医生对该前沿新药的认识。.
    [Abstract] [Full Text] [Related] [New Search]